Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chi Sheng Pharma & Biotech CoROCO:4111 +0.33%84 Interest Coverage is 414.97 as of Dec. 2025, which is 108% above its 10-year median of 199.57. GuruFocus rates ROCO:4111 with a GF Score™ of 84/100 and a GF Value™ of NT$33.14 (Fairly Valued). The stock has 1 warning sign investors should review. Among 466 Medical Devices & Instruments companies, Chi Sheng Pharma & Biotech Co ranks better than 87.34% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Chi Sheng Pharma & Biotech Co's
Operating Income
for the
three
months ended in Dec. 2025 was NT$51 Mil. Chi Sheng Pharma & Biotech Co's Interest Expense for the
three
months ended in Dec. 2025 was NT$-0 Mil.
Chi Sheng Pharma & Biotech Co's interest coverage for the quarter that ended in Dec. 2025 was 414.97.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Chi Sheng Pharma & Biotech Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Chi Sheng Pharma & Biotech Co's Interest Coverage or its related term are showing as below:
ROCO:4111'
s Interest Coverage Range Over the Past 10 Years
Min: 41.93 Med: 199.57 Max: 466.43
Current: 385.52
ROCO:4111's Interest Coverage is ranked better than 87.34% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 16.08
vs ROCO:4111: 385.52
Chi Sheng Pharma & Biotech Co (ROCO:4111) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Chi Sheng Pharma & Biotech Co Interest Coverage Related Terms
Chi Sheng Pharma & Biotech Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Chi Sheng Pharma & Biotech Co Interest Coverage Chart
ROCO:4111 vs ISRG, BDX, MDLN: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chi Sheng Pharma & Biotech Co Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Chi Sheng Pharma & Biotech Co's Interest Coverage falls into.
Chi Sheng Pharma & Biotech Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a Interest Coverage of 414.97 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. This is 108% above median its historical median of 199.57. Over the past decade, Chi Sheng Pharma & Biotech Co's Interest Coverage has ranged from 41.93 to 466.43. According to the industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #59 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 12.7%.
Is Chi Sheng Pharma & Biotech Co's Interest Coverage too high?
Chi Sheng Pharma & Biotech Co's current Interest Coverage of 414.97 is 108% above median its 10-year median of 199.57. Over the past 10 years, this metric has ranged from a low of 41.93 to a high of 466.43. The Medical Devices & Instruments industry median Interest Coverage is 16.08. Chi Sheng Pharma & Biotech Co's value of 414.97 is 2480.7% above this industry median. Based on the distribution chart, Chi Sheng Pharma & Biotech Co ranks #59 out of 466 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's Interest Coverage compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #59 out of 466 companies for Interest Coverage. This places Chi Sheng Pharma & Biotech Co in the top 13% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 16.08. Chi Sheng Pharma & Biotech Co's value of 414.97 is 2480.7% above this benchmark. Historically, Chi Sheng Pharma & Biotech Co's own Interest Coverage has ranged from 41.93 to 466.43 over the past decade. While the company's 10-year median is 199.57 vs. the industry median of 16.08, Chi Sheng Pharma & Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.08, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chi Sheng Pharma & Biotech Co's current Interest Coverage of 414.97 is 2480.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chi Sheng Pharma & Biotech Co's current Interest Coverage is 414.97, which is 108% above median its own 10-year median of 199.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$30.05 — trading 9.3% below its estimated fair value. The current Interest Coverage is 414.97, which is 108% above median its 10-year median of 199.57 and 2480.7% above the Medical Devices & Instruments industry median of 16.08. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current Interest Coverage is 414.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued.
The current stock price of NT$30.05 is trading 9.3% below its estimated GF Value™ of NT$33.14.
GuruFocus considers Chi Sheng Pharma & Biotech Co to be Fairly Valued.
Key valuation signals for ROCO:4111:
Interest Coverage: 414.97 (108% above median its 10-year median of 199.57)
GF Value™: NT$33.14 vs. price of NT$30.05 (9.3% below fair value)
Industry Position: 2480.7% above the Medical Devices & Instruments median (#59 of 466)
No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chi Sheng Pharma & Biotech Co Business Description
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
84GF Score
Get the complete analysis for ROCO:4111
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4111 has been successfully added to your 
